Pricing Trends and Overlapping Indications of Checkpoint Inhibitors for Cancer Treatment

Despite the introduction of 11 FDA-approved checkpoint inhibitors for the treatment of cancer between 2015 and 2024, prices for this drug class decreased only slightly, in part because nearly half of approved indications were unique to a single drug, limiting direct competition. Expanding price negotiations and incentivizing comparative effectiveness research could help address persistent high prices for these therapies.